Abstract A reciprocal regulation exists between the central nervous and immune systems through which the CNS signals the immune system via hormonal and neuronal pathways and the immune system signals the CNS through cytokines. The primary hormonal pathway by which the CNS regulates the immune system is the hypothalamic-pituitary-adrenal axis, through the hormones of the neuroendocrine stress response. The sympathetic nervous system regulates the function of the immune system primarily via adrenergic neurotransmitters released through neuronal routes. Neuroendocrine regulation of immune function is essential for survival during stress or infection and to modulate immune responses in inflammatory disease. Glucocorticoids are the main effector end point of this neuroendocrine system and, through the glucocorticoid receptor, have multiple effects on immune cells and molecules. This review focuses on the regulation of the immune response via the neuroendocrine system. Particular details are presented on the effects of interruptions of this regulatory loop at multiple levels in predisposition and expression of immune diseases and on mechanisms of glucocorticoid effects on immune cells and molecules.
GENERAL INTRODUCTION
The immune system has for many years been known to be influenced by glucocorticoids, and glucocorticoids have been used in the treatment of inflammatory diseases since the 1940s. In fact, Kendall, Reichstein, and Hench received the Nobel Prize for this discovery in 1950 (1). Since then extensive research has shown the pharmacological effects of glucocorticoids on many aspects of immune cell function (2, 3). However, until recently the fact that glucocorticoids play an essential physiological role in regulation of the immune system in health and disease was not fully appreciated. An understanding of the physiological mechanisms involved in glucocorticoid secretion and their regulation of the immune system under both normal and disease conditions is fundamental to our understanding of the pathogenesis of inflammatory disease and ultimately for the development of effective therapies for such diseases.
Recent studies have shown that this physiological regulation of the immune system by glucocorticoids is only one part of an extensive regulatory network between the central nervous system (CNS), neuroendocrine system, and immune system. This network of connections through nerve pathways, hormonal cascades, and cellular interactions allows the CNS to regulate the immune system locally at sites of inflammation, regionally in immune organs, and systemically though hormonal routes. In turn through similar connections, the immune system also regulates the CNS. During inflammation, cytokines produced at the inflammatory site can signal to the brain and produce the symptoms of sickness behavior and fever (4, 5) . Cytokines are also expressed in areas of the brain, e.g., glia, neurons, and macrophages, and play a role in both neuronal cell death (6, 7) and survival (8) . Cytokine-mediated neuronal cell death is thought to play an important role in several neuro-degenerative diseases, such as neuro-AIDS, Alzheimer's, multiple sclerosis, stroke, and nerve trauma. In addition to this growth-factor role when expressed within the CNS, cytokines produced in the periphery can function as hormones and can stimulate the CNS by several mechanisms. They can pass the blood-brain barrier (BBB) at leaky points, for example at the organum vasculosum lamina terminalis (OVLT) or median eminence. They may be actively transported across the BBB in small amounts (9) . In addition they can rapidly signal the CNS through the vagus nerve (10, 11) . They can influence the brain by activation of second messengers, such as nitric oxide and prostaglandins, after binding to receptors on endothelial cells (12, 13) . While a full understanding of this bidirectional communication between the CNS and immune systems is important, this chapter focuses only on the regulation of the immune system by the CNS, mainly though the neuroendocrine system and the adrenergic system. For further information on the regulation of the CNS by the immune system see the review by Mulla & Buckingham (14) .
The CNS regulates the immune system through two major mechanisms: (a) the hormonal stress response and the production of glucocorticoids, and (b) the autonomic nervous system with the release of noradrenalin. The CNS can also regulate the immune system locally via the peripheral nerves with release of neuropeptides such as substance P and locally produced corticotrophin-releasing hormone (CRH). This latter mechanism is not the focus of this review; for further information on these refer to the following articles (15, 16) .
The main regulator of the glucocorticoid effect on the immune system is the hypothalamic-pituitary-adrenal axis (HPA axis) (Figure 1) . The main components of the HPA axis are the paraventricular nucleus (PVN) in the hypothalamus of the brain, the anterior pituitary gland located at the base of the brain, and the adrenal Figure 1 Diagram of the routes of communication between the brain and immune system, including the HPA axis, sympathetic nervous system, and cytokine feedback to the brain. glands. CRH is secreted from the PVN of the hypothalamus into the hypophyseal portal blood supply and stimulates the expression of adrenocorticotropin hormone (ACTH) in the anterior pituitary gland. ACTH then circulates in the bloodstream to the adrenal glands where it induces the expression and release of glucocorticoids.
The HPA axis is subject to regulation both from within the central nervous system and from the periphery. Glucocorticoids, themselves, feed back to negatively regulate the HPA axis, exerting their negative feedback at the hypothalamic and pituitary level. The HPA axis can also be regulated by other factors such as the sympathetic nervous system, cytokines, and other neuropeptides, such as arginine vasopressin (AVP) (17) . CRH is also negatively regulated by ACTH and itself, as well as by other neuropeptides and neurotransmitters in the brain, e.g., γ -aminobutyric acid-benzodiazopines (GABA-BDZ) and opioid peptide systems. CRH is positively regulated by serotonergic, cholinergic, and histaminergic systems (18) .
The connections between the neuroendocrine system and immune system provide a finely tuned regulatory system required for health. Disturbances at any level of the HPA axis or glucocorticoid action lead to an imbalance of this system and enhanced susceptibility to infection and inflammatory or autoimmune disease. Overstimulation of the HPA axis with excessive amounts of circulating glucocorticoids and overall suppression of immune responses lead to enhanced susceptibility to infection, whereas understimulation results in lower circulating levels of glucocorticoids and susceptibility to inflammation. Dysregulation may also occur at the molecular level and in this instance would result in glucocorticoid resistance at a molecular level leading to enhanced susceptibility to inflammation. A detailed understanding, therefore, by which the CNS and neuroendocrine systems regulate the immune system at the systemic, anatomical, cellular, and molecular levels will inform not only the pathogenesis and treatment of inflammatory/autoimmune conditions and infectious disease but also conditions predisposing to susceptibility and resistance to these illnesses.
EVIDENCE FOR ROLE OF ENDOGENOUS GLUCOCORTICOIDS IN REGULATION OF IMMUNE FUNCTION
Changes in the levels of circulating glucocorticoids, such as during exercise and with circadian rhythms, are associated with changes in cytokine levels and production by leukocytes (19) (20) (21) (22) (23) . Such studies provide circumstantial evidence that physiological fluctuations in glucocorticoid levels, in the range of those seen with circadian variations or stress, are associated with altered immune function. However, animal models have provided the strongest proof that endogenous glucocorticoids are essential physiological regulators of the immune response and inflammatory/autoimmune disease.
Inbred rat strains, in which altered neuroendocrine responsiveness is associated with differential susceptibility and resistance to autoimmune/inflammatory disease, provide a naturalistic, genetically uniform system that can be systemically manipulated to test the role of neuroendocrine regulation of various aspects of immunity. Lewis (LEW/N) rats are an inbred strain of rats that are highly susceptible to development of a wide range of autoimmune/inflammatory diseases in response to a variety of antigenic or proinflammatory stimuli. Largely histocompatible Fischer (F344/N) rats are relatively resistant to these same illnesses after exposure to the same dose of antigens. These two strains also show related differences in HPA axis responsiveness, with inflammatory-susceptible LEW/N exhibiting a blunted response, compared to inflammatory-resistant F344/N rats with an excessive HPA response compared to outbred rats (24) (25) (26) (27) (28) . Differences in the expression of hypothalamic CRH (26), pro-opiomelanocortin (POMC) (28), corticosterone-binding globulin (CBG) (27), and glucocorticoid receptor (GR) expression and activation (27, 29, 30) have been shown in these two rat strains. A variety of surgical or pharmacological HPA axis interventions in these strains of rats, as well as in mouse strains, alter the course and severity of inducible autoimmune/inflammatory disease. Thus, in F344/N rats, treatment with the glucocorticoid antagonist RU486 is associated with high mortality and development of arthritis in response to injection of streptococcal cell walls (25). Approximately 50% of rats die after infection with Salmonella typhimurium, but adrenalectomized rats suffer 100% lethality after infection with this bacteria (31). Similarly, in mice, adrenalectomy before infection with CMV virus results in lethality but glucocorticoid replacement prevents virus-induced lethality (32). The high rates of mortality within 12-24 h of exposure to this wide range of antigenic, proinflammatory, or infectious stimuli across species and strains in which the HPA axis has been interrupted pharmacologically or surgically, indicates the importance of an intact HPA axis to protect against septic shock.
It is also possible in animal models to attenuate inflammatory disease by reconstituting the HPA axis, pharmacologically with glucocorticoids, or surgically by intracerebral fetal hypothalamic tissue transplantation. In LEW/N rats either treated with low-dose dexamethasone (25) or transplanted intracerebroventricularly with F344/N hypothalamic tissue (33), arthritis and carageenan inflammation are significantly attenuated. Experimental allergic encephalomyelitis (EAE) is inducible in LEW/N rats by immunization with myelin basic protein. After initial immunization these animals experience transient paralysis but then recover to some extent. During the development of the disease and recovery, the production of endogenous corticosterone increases, which is essential for survival of the animal. If this endogenous production is interrupted by adrenalectomy, the development of EAE is fatal. Whereas a subcutaneous steroid implant equivalent to the basal corticosterone levels does not reduce mortality, a dose equivalent to the EAE-induced corticosterone levels results in survival rates similar to that of normal animals, but EAE still develops. If a subcutaneous implant of even higher corticosterone levels is used, however, the animal will undergo complete remission (34).
Such animal studies showing that interruption of the HPA axis predisposes to worse inflammation, while reconstitution attenuates autoimmune/inflammatory disease, lend support to the role of glucocorticoid imbalance in exacerbation of human autoimmune, inflammatory, allergic, or infectious diseases. Thus, a blunted HPA axis response to pituitary adrenal axis stimulation with CRH or insulin, or by psychological stress, has been shown in a variety of autoimmune diseases including rheumatoid arthritis, SLE, Sjogren's syndrome, fibromyalgia, and chronic fatigue syndrome, as well as in allergic asthma and atopic dermatitis. Conversely, in humans, excess chronic stimulation of the hormonal stress response with concomitant chronically elevated glucocorticoids, as occurs in chronic stress situations is associated with an enhanced susceptibility to viral infection, prolonged wound healing, or decreased antibody production after vaccination (35-38). Such stress is experienced by caregivers of Alzheimer's patients, students taking exams, couples during marital conflict, and Army Rangers undergoing extreme exercise and stress. One important mechanism by which activation of the HPA axis regulates these immune responses and severity of expression of resultant disease is through the effects of glucocorticoids at the molecular level though the glucocorticoid receptor (GR). The next sections describes this important receptor system and its regulation of target gene expression.
PHARMACOLOGICAL VERSUS PHYSIOLOGICAL EFFECTS OF GLUCOCORTICOID
When considering the physiological relevance of the effects of glucocorticoids on immunity, it is important to recognize that glucocorticoids in pharmacological doses or forms exert different effects than they do under physiological conditions. Physiological concentrations of glucocorticoids in the range of 350 nmol/l to 950 nmol/l, such as occur during physical or psychological stress, result in modulation of transcription of genes involved in the inflammatory response, whereas pharmacological doses (higher concentration than physiological) result in a total suppression of the inflammatory response. There are also differences in potency of immune suppression by synthetic glucocorticoids, such as dexamethasone, versus the effects on immune response to natural glucocorticoids, such as hydrocortisone. For example, the synthetic glucocorticoid dexamethasone exerts a greater suppression of IL-12 than does the natural glucocorticoid hydrocortisone, which is consistent with the greater affinity of dexamethasone than hydrocortisone for GR (39).
MODULATION OF THE IMMUNE SYSTEM BY GLUCOCORTICOIDS
There are two receptors for glucocorticoids, the glucocorticoid receptor and the mineralocorticoid receptor (MR). Corticosterone has a lower affinity for MR than for GR. Thus, at low levels, glucocorticoids bind preferentially to MR, and only at high levels, i.e., during stress, is GR occupied (39, 41). MR and GR, which are colocalized in some areas of the brain and in lymphocytes, can bind as heterodimers to DNA (42, 43), which could have implications for gene transcription or transrepression. In the brain, MR has been implicated in a proactive mode, in the prevention of disturbance of homeostasis, whereas GR has been suggested to work in a reactive mode in the recovery from a disturbance (39, 44). The primary receptor for glucocorticoids in immune cells is GR. The availability of glucocorticoids is also dependent on the expression of 11β-hydroxysteroid dehydrogenase, an enzyme responsible for the conversion of steroids from the active form, e.g., cortisol and corticosterone, into an 11-keto inactive form, e.g., cortisone and 11-dehydrocortisone. Two forms of this enzyme exist. The type I enzyme is expressed in liver, brain, adipose tissue, lung, and other glucocorticoid-target tissues and catalyzes the regeneration of active glucocorticoids from the inactive 11-keto form. Conversely, the type II enzyme catalyzes the inactivation of glucocorticoids to the inert 11-keto form (45).
Glucocorticoid Receptor and Mechanism of Action
The end point tissue effect of glucocorticoids is mediated by GR (NR3C1) (46). This is a member of the steroid and thyroid hormone receptor superfamily along with the progesterone, estrogen, mineralocorticoid, and thyroid receptors, and GR essentially is a ligand-dependent transcription factor. These receptors all have a similar structure that can be divided into three distinct regions (Figure 2 ). The N-terminal domain is involved in transactivation; the middle section is termed the DNA-binding domain (DBD) and is involved in DNA binding mediated via two zinc fingers; and the C-terminal domain or ligand-binding domain (LDB) is responsible for ligand binding as well as being also involved in transactivation, dimerization, and hsp90 binding (2, 47).
Glucocorticoids circulate in the plasma associated with CBG or albumin. It is generally thought that glucocorticoids enter the cell by passive diffusion, although there is evidence for an active transport out of the cell. GR is located in the cytoplasm in the unactivated state in a multiprotein complex containing hsp90 and immunophilins. These are thought to hold the GR in a conformation that is available to the ligand. Upon ligand binding, GR dissociates from this complex and translocates to the nucleus where it binds as a homodimer to target elements or glucocorticoid response elements (GREs) via its zinc fingers of the DBD. The bound GR homodimer can then modulate gene expression by modulating the basal transcription machinery either directly or via cofactors (Figure 3) . GR has been involved in both the upregulation and downregulation of genes. Downregulation of gene expression can occur via so-called negative glucocorticoid response elements (nGRE), e.g., the POMC gene, but mostly gene repression by GR occurs via its interaction with other transcription factors such as AP-1 and NFκB (2, 48). It is noteworthy that the reverse can also occur, i.e., AP-1 and NFκB are able to repress GR function.
When GR was first cloned, two clones for GR were found that differed in the C terminus (49). This second receptor, GRβ, is a splice variant of GR that is identical to GR but is lacking the last 50 amino acids. Instead it has a unique 15-amino acid C terminus. This receptor is located in the nucleus regardless of ligand status, but it can also be found in the cytoplasm complexed to hsp90. It does not bind ligand and does not activate gene transcription but may act as a dominant negative receptor in vitro by forming transcriptionally inactive heterodimers with GRα (50-52). This mechanism of a dominant negative receptor is still under dispute as other studies have shown no effect of GRβ on GRα-mediated transactivation or transrepression (53-55).
AP-1
GR can modulate gene expression via interaction with other factors, such as NFκB and AP-1. AP-1 consists of a heterodimer of the oncoproteins c-Fos and c-Jun that bind to an AP-1 consensus binding site in DNA to activate gene transcription in response to ligands such as phorbol esters. Although the high-affinity Fos/Jun heterodimers predominate, the lower-affinity Jun/Jun homodimers are also capable of binding to the AP-1 site. Glucocorticoids can reduce the DNA-binding ability of the Fos and Jun complexes by protein-protein interactions and thereby repress AP-1-mediated gene activation (56, 57) ( Figure 4 ). This can also occur through a composite GRE. This sequence contains a binding site for the receptor and also for a nonreceptor factor. For example, GR was shown to repress AP-1 activity at the composite GRE in the promoter of the plfG gene; this repression was mediated by the N-terminal domain of GR and could not be mediated by MR (58, 59).
One example of a gene where a composite HRE is involved in the repression of the gene by glucocorticoids is the hypothalamic hormone CRH. The promoter of this gene contains an AP-1 site closely located to a GRE, and repression of the AP-1-activated gene transcription by glucocorticoids has been shown (60). This could be the mechanism by which glucocorticoids exert their negative feedback on the hypothalamus to downregulate the HPA axis.
NFκB
Glucocorticoids play a role in immunosuppression through their repression of NFκB, which is a major factor involved in the regulation of cytokines and other immune responses. [For comprehensive reviews on NFκB, see Baldwin (61), Ghosh et al. (62) , and McKay & Cidlowski (48)]. NFκB was originally described as a dimer of two proteins p65 (RelA) and p50 (NF-κB1), but a whole family of these proteins has now been described. These proteins all contain a highly conserved 300-amino acid domain termed the Rel homology domain (RHD), which is important for DNA binding and nuclear translocation and dimerization. The proteins p65 (Rel A), C Rel, and Rel B contain a C-terminal transactivation domain, whereas p50 (NF-κB1) and p52 (NF-κB2) are present as precursors (p105 and p100, respectively), which contain a C-terminal IκB-like region that is removed by proteolysis. The ability of these proteins to form various dimer partners and the specificity of these dimers for different DNA sequences may be fundamental to the cellspecific responses mediated by NFκB. These proteins are present in the cytoplasm as complexes together with the inhibitory protein IκB. This is also now known to be part of a family of proteins that include IκBα, IκBβ, IκBγ , IκB-R, and the C-termini of p105/p50 and p100/p52. These all contain multiple ankyrin repeats, which are involved in protein-protein interactions between the IκB and NFκB, and a C-terminal PEST sequence, which is a signal for protein degradation (48).
NFκB is normally located in the cytoplasm associated with the inhibitor IκB protein. Upon activation, IκB is phosphorylated, ubiquinated, and then degraded. The free NFκB can then translocate to the nucleus where it activates gene expression. NFκB can be stimulated by a variety of factors, including proinflammatory cytokines such as TNF-α and IL-1, physical or oxidative stress, and bacterial or viral proteins (48, 63) ( Figure 4 ).
There have been two schools of thought regarding GR-mediated repression of NFκB, and data exist to support both. One is that glucocorticoids via GR induce the expression of the inhibitory protein IκB that then sequesters NFκB in the cytoplasm and prevents it from translocating to the nucleus and inducing gene activation (63, 64) . This mechanism of repression of NFκB by GR may be limited to certain cell types, particularly monocytes and lymphocytes. The other model suggests that there is a physical interaction or cross-talk between NFκB and GR that prevents gene expression (63, (65) (66) (67) (68) (69) (70) (71) . In some cases GR-induced transcription is not required, as the anti-glucocorticoid RU486 is also capable of inhibiting NFκB to some extent (67, 72) . The region of the GR required for GR repression of NFκB has been located to the zinc finger region of the DNA-binding region of GR (63, 67) . This region has been further defined as two amino acids in the C-terminal zinc finger that are absolutely critical for GR-mediated repression of NFκB; these residues are not involved in GR-mediated repression of AP-1 (73). It is plausible that these two models are not mutually exclusive or that they are dependent on cell type. One experiment in the A549 pulmonary epithelial cell line has shown that both these models exist in the same system. In this case, dexamethasone does induce IκB expression, but when protein synthesis and therefore IκB production is blocked, GR is still able to repress NFκB-mediated gene activation although not to the same extent as when protein synthesis is allowed (74) .
It has also been suggested that glucocorticoid repression of NFκB activity could be caused by competition between GR and NFκB for limited cofactors such as CREB-binding protein (CBP) and steroid receptor coactivator 1 (SRC-1), as it has been shown in Cos cells that this repression can be alleviated by excess cofactor (75) . McKay & Cidlowski, however, showed that CBP did not mediate GR repression of NFκB by a competitive model, but rather that CBP functioned as an integrator to enhance the physical interaction between GR and NFκB (76) . The catalytic subunit of protein kinase A (PKAc) has also been suggested to promote the cross-talk between GR and NFκB (77).
REGULATION OF IMMUNE-RELATED GENES
Glucocorticoids regulate a wide variety of immune cell functions and expression of immune molecules through the molecular mechanisms described above. Thus, glucocorticoids modulate cytokine expression, adhesion molecule expression and immune cell trafficking, immune cell maturation and differentiation, expression of chemoattractants and cell migration, and production of inflammatory mediators and other inflammatory molecules [for reviews see Barnes (78) and Adcock (2)].
Cytokine Expression
Glucocorticoids modulate the transcription of many cytokines. They suppress the proinflammatory cytokines IL-1, IL-2, IL-6, IL-8, IL-11, IL-12, TNF-α, IFN-γ , and GM-CSF while upregulating the anti-inflammatory cytokines IL-4 and IL-10.
PROINFLAMMATORY CYTOKINES Glucocorticoids mediate the anti-inflammatory response by downregulating the expression of proinflammatory cytokines such as IL-1, IL-6, and TNF-α. Glucocorticoids have been shown to downregulate the transcription of IL-1β, to destabilize IL-1β mRNA (79) (80) (81) , and to downregulate IL-1α (82) . They also upregulate the expression of the decoy IL-1 receptor, IL-1R II (83) .
Glucocorticoids regulate IL-6 production not only directly, but also indirectly, through their effects on the cytokines that regulate IL-6. IL-1 or TNF induction of IL-6 is mediated via NFκB and by another nuclear factor, NF-IL6, in transfection studies of these nuclear factors and the IL-6 promoter in HeLa and F9 cells. This IL-1-induced induction of IL-6 can be inhibited by glucocorticoid-activated GR via protein-protein interactions at the C-terminal transactivation domain of NFκB (65, 69, 84) . This repression does not require protein synthesis and does not affect the DNA-binding capacity of NFκB (69) . Glucocorticoids also inhibit expression of IL-11, a member of the IL-6 cytokine family, by inhibition of gene expression and by destabilization of mRNA (85) .
Evidence for these molecular mechanisms of GC regulation of cytokines has appeared in vivo in disease states. In rheumatoid arthritis patients, administration of glucocorticoids leads to a decrease in the release of TNF-α into the bloodstream (86) . The LPS-stimulated production of TNF-α in monocytes is reduced by glucocorticoid treatment. The promoter of TNF-α does not contain a typical GRE site, and so this repression by glucocorticoids may occur via other factors involved in the regulation of TNF-α which have binding sites in the promoter, such as NFκB and AP-1 (87). However, some evidence suggests that the glucocorticoid-mediated repression of TNF-α could occur at the level of translation rather than transcription (88) .
The transcription of other proinflammatory cytokines is also affected by glucocorticoids. IFN-γ expression in spleen cells, and blood monocytes is inhibited by glucocorticoids (89, 90) . Dexamethasone inhibits basal IL-8 in airway epithelial cells by destabilizing the mRNA via new protein synthesis (91) . The expression of the Th1 cytokine IL-12 and its receptor is downregulated by glucocorticoids (92) (93) (94) . Effects of glucocorticoids on IL-12 are fully discussed in the section on Th1-Th2 shift.
IL-2 expression in spleen cells is inhibited by glucocorticoids (89), and dexamethasone inhibits the ionomycin-and TPA-induced IL-2 expression in FJ8.1 cells. With the promoter for IL-2, the dexamethasone-induced repression inhibits the binding of NFκB and reduces the binding of AP-1 to DNA. Glucocorticoids not only affect the action of cytokines by affecting their expression, but they also can inhibit their signaling mechanisms. Thus IL-2 signaling via the Jak-STAT cascade can be inhibited by dexamethasone (95) .
Granulocyte-macrophage colony stimulating factor (GM-CSF) is a proinflammatory mediator. IL-1β-stimulated GM-CSF in bronchial epithelial cells is inhibited by dexamethasone by transcriptional mechanisms (96) .
ANTIINFLAMMATORY CYTOKINES The major Th2 cytokine is IL-10. In blood monocytes varying effects of glucocorticoids, both synthetic and natural, on IL-10 have been reported that are dependent on the dose. Low physiological doses of glucocorticoids suppress IL-10 expression, whereas high pharmacological doses enhance IL-10 expression (39, 97a).
IL-4 is a Th2-associated cytokine that is important for the proliferation of mast cells and attraction of eosinophils to areas of inflammation during response to IgE stimuli or allergic reactions. Dexamethasone downregulates IL-4 mRNA in mast cells (98, 99) and in lymphocytes (82) . The effect of dexamethasone on IL-4 production in T cells is a matter of some controversy and can be at least partially explained by consideration of the doses used experimentally. As IL-4 is a Th2-associated cytokine and since glucocorticoids induce a shift from Th1-Th2 immunity (see later section), one might expect dexamethasone to induce IL-4 expression. Indeed, in the lymph nodes and spleen of mice IL-4 is induced in response to physiological concentrations of glucocorticoids both in vivo and in vitro (100, 101) . On the other hand, consistent with the efficiency of glucocorticoids in the treatment of allergic diseases, data also exist showing that stress levels of dexamethasone downregulate IL-4 expression in T cells (89) .
Cell Adhesion Molecules and Immune Cell Trafficking
Glucocorticoids reduce the trafficking of leukocytes to areas of inflammation. This occurs via the downregulation of protein molecules involved in the attraction and adhesion of leukocytes to these areas. Dexamethasone inhibits the expression of intracellular adhesion molecule 1 (ICAM-1), endothelial-leukocyte adhesion molecule 1 (ELAM-1) (102) , and vascular adhesion molecule 1 (VCAM-1) (103) . Glucocorticoids can inhibit the expression of ICAM-1 through inhibition of the NFκB site in the promoter of the ICAM-1 gene (66, 71, 74) . Glucocorticoids inhibit TNF-α-induced VCAM-1 expression but not ICAM-1 in bronchial epithelial cells. NFκB sites have been identified in the promoter of VCAM-1, and it has been suggested that glucocorticoid repression of this gene may occur through GR-mediated repression of NFκB (103) . E-selectin is an endothelial cell surface adhesion molecule that is important for the recruitment of leukocytes from the blood. It is upregulated by IL-1β and TNF-α and its expression can be repressed by glucocorticoids. Repression by glucocorticoids does not affect NFκB translocation or binding to DNA, which suggests interference in transcriptional activation of NFκB (70) . L-selectin is involved in the attachment of blood leukocytes during inflammation, and its expression is decreased by glucocorticoid treatment in bone marrow cells and polymorphonuclear cells (104) .
Chemoattractants and Cell Migration
Cytokine-induced neutrophil chemoattractant (CINC)/gro is a chemoattractant for neutrophils and is therefore important for the accumulation of neutrophils at sites of inflammation. It is also proposed to be a member of the family that includes IL-8. mRNA for CINC/gro is induced by IL-1β via NFκB, and this induction can be inhibited by glucocorticoids, which prevent the translocation of NFκB to the nucleus and therefore prevent DNA binding and gene transcription (105) .
IL-5 is a chemoattractant for eosinophils and is important for the accumulation of eosinophils in inflammatory diseases such as asthma. IL-5 mRNA can be downregulated by glucocorticoids in mast cells (99) and T cells (106) . IL-5 can be induced by TCR and IL-2 by different mechanisms, and both of these can be repressed by glucocorticoids. The mechanism of glucocorticoid repression of TCR-induced IL-5 possibly occurs through AP-1 and NFκB, but these factors are not involved in the glucocorticoid repression of IL-2-induced IL-5 (107) .
RANTES (regulated upon activation normal T cell expressed and secreted) is a chemoattractant involved in the recruitment of eosinophils to areas of inflammation. Dexamethasone inhibits mRNA expression in activated and nonactivated cells (108, 109) . The cytokines monocyte chemoattractant protein 1 (MCP-1), MCP-2, and MCP-3 are downregulated by dexamethasone (108) . Downregulation of MCP-1 occurs posttranscriptionally by destabilization of the mRNA at the 5 end, although the exact mechanism is unknown (110) .
Eotaxin is an eosinophil chemoattractant involved in the accumulation of eosinophils in the airways in response to allergic stimuli. Eotaxin mRNA is stimulated by cytokines such as TNF-α and IL-1β and this cytokine-induced induction is repressed by glucocorticoids (111).
Production of Inflammatory Mediators
Glucocorticoids also affect the production of inflammatory mediators including prostaglandins and nitric oxide. Glucocorticoids suppress prostaglandin synthesis at sites of inflammation by several mechanisms. The key stages during the synthesis of prostaglandin are the release of arachadonic acid from membrane phospholipids, which is catalyzed by phospholipase A 2 (PLA 2 ), and the subsequent conversion to PGH 2 by the action of cyclooxygenase (COX). There are two isoforms of PLA 2 , secretory PLA 2 and cytosolic PLA 2 . There are also two COX enzymes; COX-1 is constitutively expressed, and COX-2 is inducible and thought to be involved in stimuli-induced prostaglandin synthesis. COX-2 induction by inflammatory stimuli is mediated though NF-IL6 and NFκB regulatory sequences in its promoter (112) . Glucocorticoids exert their effect by repression of cytosolic PLA 2 and COX-2 mRNA levels (113) (114) (115) .
Nitric oxide synthase II (NOS II) is the enzyme that produces nitric oxide (NO). NO has been implicated in autoimmune and inflammatory responses. The promoter of NOS II contains a binding site for NFκB, which is required for the cytokine induction of this gene. Glucocorticoids repress the cytokine induction of NOS II, and this repression does not correspond with an induction of the IκB gene, thereby implicating a method of protein-protein interaction for this repression (68) . iNOS is an inducible form of nitric oxide synthase and is another enzyme involved in the synthesis of nitric oxide. Dexamethasone inhibits transcription of the iNOS gene in rat hepatocytes by the induction of IκB (116).
Lipocortin 1 (or annexin 1) is expressed in many immune cells and is also expressed in the neuroendocrine system in the hypothalamus and pituitary. It has anti-inflammatory actions although these mechanisms are not fully understood. One way in which lipocortin 1 exerts its anti-inflammatory action in the periphery is by the inhibition of prostaglandin synthesis via the inhibition of release of arachadonic acid, although the exact mechanism is not known. Glucocorticoids have a dual action on lipocortin 1. Lipocortin 1 is normally expressed and localized mainly in the cytoplasm, but it is also localized to the external surface of cell membranes. Upon glucocorticoid exposure, the amount of lipocortin 1 on the external membrane rapidly increases. This externalization is followed by an increase in lipocortin 1 synthesis by the cells in response to glucocorticoids (117) .
Other Factors Involved in the Inflammatory Response
The β 2 -adrenoreceptor is involved in the adrenergic control of the immune system (see later section). Glucocorticoids increase the transcription of the β 2 -adrenoreceptor in many cell types, including airway epithelial cells. This transcriptional regulation occurs via a GRE sequence in the promoter of the gene (118, 119) . Other receptors involved in the regulation of the immune system are regulated by glucocorticoids. The transcription of the NK 1 -receptor, the receptor for substance P, is inhibited by glucocorticoids probably through an AP-1 site (120) . The NK 2 -receptor is also downregulated by glucocorticoids (121) .
EFFECTS ON IMMUNE CELLS
Glucocorticoids, in general, suppress maturation, differentiation, and proliferation of immune cells involved in all aspects of immunity, including innate, T cell, and B cell function and chronic allergic reactions.
Innate Immunity
Monocytes are produced in the bone marrow. Once mature they leave, circulate in the bloodstream, and after a time enter the tissues and become macrophages. During inflammation, circulating monocytes migrate to the inflammatory site where they become activated. Glucocorticoids interfere with the protective and defense mechanisms of activated macrophages, rather than resident macrophages. This occurs via their effects on cytokines and other inflammatory mediators such as prostaglandin synthesis (122) . Glucocorticoids at pharmacological concentrations induce apoptosis in macrophages and monocytes; and the pro-inflammatory cytokine IL-1β may be involved in prevention of apoptosis, whereas the antiinflammatory cytokines IL-4 and IL-10 induce apoptosis in these cells (81) . Thus, pharmacological or stress levels of glucocorticoids reduce circulating numbers of monocytes, inhibit secretion of IL-1, IL-6, TNF-α, and monocyte chemotactic activating factors, and impair synthesis of collagenase, elastase, and tissue plasminogen activator (123) .
Neutrophils are involved in the tissue damage that occurs during the innate inflammatory phase of inflammatory disease. In response to injury, neutrophils migrate out of the circulating bloodstream, extravasate between endothelial cells, and move to the site of inflammation. Glucocorticoids affect the activation of neutrophils and also the functions of neutrophils, such as chemotaxis, adhesion, transmigration, apoptosis, and phagocytosis (123, 124) . Glucocorticoid regulation of these functions in neutrophils is due to numerous components including regulation of cytokines. However, lipocortin 1 also plays a pivotal role in glucocorticoidinduced responses. Glucocorticoids have a dual effect on neutrophils. On one hand pharmacological doses are inhibitory and suppress the inflammatory response caused by neutrophil activation and migration. On the other hand, neutrophils are required for the response to bacterial infections, and as such their circulating numbers are increased by pharmacological doses of glucocorticoids through inhibition of apoptosis (124) .
Th1-Th2
Glucocorticoids induce a shift from a Th1 to a Th2 pattern of immunity. As previously mentioned, glucocorticoids can affect the transcription of many cytokines, generally upregulating antiinflammatory cytokines and downregulating proinflammatory cytokines, thereby causing a shift from Th1 to Th2 immunity. The glucocorticoid-induced shift of Th1 to Th2 may be due mainly to downregulation of the Th1 cytokines, thus allowing dominant expression of the Th2 cytokines (126, 127) . They modulate the expression of IL-12 or its receptor, and this regulation of IL-12 is thought to be a major mechanism by which glucocorticoids mediate the Th1-Th2 shift (94) . This glucocorticoid-mediated downregulation of IL-12 occurs by inhibition of Stat4 phosphorylation in the signaling cascade downstream of IL-12, and this inhibition is mediated by GR. This is specific for the Th1-mediated immunity because phosphorylation of Stat6, which is involved in the signal cascade from IL-4, is not affected by glucocorticoids (93) . Glucocorticoids downregulate the IL-12 receptor β1-and β2-chains, but this downregulation occurs after 3 days of treatment, whereas the inhibition of Stat4 phosphorylation is seen within 2 h, suggesting that IL-12 receptor downregulation occurs in response to prolonged glucocorticoid exposure (92, 93) . Several other neural factors besides glucocorticoids can also induce a Th1-Th2 shift; these neural factors include the sympathetic neuropeptides, noradrenalin, and adrenalin (94) .
Glucocorticoids differentially affect the survival of Th1 and Th2 cells. Th2 NK1.1 + T cells, which produce IL-4, are resistant to dexamethasone-induced apoptosis, and this resistance may be due to the expression of the proto-oncogene Bcl-2 (128).
Alterations in Th1-Th2 immunity are characteristic of some autoimmune diseases. Rheumatoid arthritis, multiple sclerosis (MS), and type I diabetes mellitus are examples of autoimmune diseases in which there is a shift toward Th1-mediated immunity with an excess of IL-12 and TNF-α production. Systemic lupus erythematosus (SLE) is shifted toward Th2-mediated immunity with an excess of IL-10 production (94). In situations where there is an excess of glucocorticoid production, e.g., in animal models with a hyperactive HPA axis (F344/N rats) or in women in the third trimester of pregnancy, there is a relative resistance to Th1-associated autoimmune diseases. Conversely, animals with a lack of glucocorticoids or a hypoactive HPA axis (LEW/N rats) are susceptible to Th1-associated autoimmune diseases (94, 129) . LEW/N rats are susceptible to EAE, a Th1-mediated autoimmune disease. Spontaneous recovery of these animals is correlated with an increase in glucocorticoids, whereas adrenalectomy results in fatal regression of the disease but can be reversed by administration of glucocorticoids, indicating the shift from Th1 to Th2 immunity (34).
Allergy
Eosinophils are critical in the response to allergic stimuli, and glucocorticoids both systemically and topically applied are effective in the treatment of these diseases. Pharmacological doses of glucocorticoids reduce the circulating numbers of eosinophils probably through many factors including IL-5, IL-3, and GM-CSF. Glucocorticoids also sequester eosinophils in primary and secondary lymphoid tissues, induce apoptosis, and inhibit the recruitment of eosinophils to areas of inflammation (123, 130, 131) .
Basophils are the least abundant circulating leukocyte but are important in IgEmediated allergic inflammation. Their activation leads to the synthesis and release of lipid mediators such as leukotriene C4 (LTC4), which induces changes in muscle and vascular tissue. Glucocorticoids reduce circulating numbers of basophils, impair histamine and leukotriene release, and inhibit basophil migration (123, 131) .
Mast cells are important for the mediation of inflammatory disease particularly in response to IgE. Glucocorticoid treatment results in a decrease in mast cells in airways, but the mechanism for this is not certain, and a direct inhibitory effect on mediator release has been disproven (132, 133).
Resident Tissue Immune Cells
Dendritic cells are involved in antigen presentation, and this could assist in the Th1-Th2 shift. Glucocorticoids reduce the number of dendritic cells in an animal model and also in human nasal mucosa after topical glucocorticoid application (134, 135). Epithelial cells are involved in inflammation in asthmatic airways, and they are also a target for glucocorticoid therapy in this disease. As described earlier, glucocorticoids inhibit the expression of cytokines, chemoattractants, and mediators of inflammation in the epithelial cells of the airways. Glucocorticoids reduce the inflammatory mediator-induced leakage of plasma proteins into the alveolar bronchi (136) . Interestingly, endothelial cells of the airways show the highest expression of GR in human lung (137) . Mucosal cells secrete mucus during inflammation. Glucocorticoids act directly on these cells and inhibit the expression of MUC2 and MUC5AC, the genes that encode mucin (138, 139) . Glucocorticoids also inhibit mucus secretion via their inhibition of inflammatory mediators.
Effects of Glucocorticoids on Lymphocyte Selection at the Cellular and Immune Organ Level
Glucocorticoids play an important role in lymphocyte selection via several mechanisms, including apoptosis and thymocyte differentiation during development.
APOPTOSIS Apoptosis is a mechanism of programmed cell death, which is necessary for a homeostasis to exist between cell death and proliferation. For a review on apoptosis, see King & Cidlowski (140) . Glucocorticoids induce G1 arrest and apoptosis in lymphoid cells. There appear to be two mechanisms for glucocorticoidmediated apoptosis in thymocytes, one for proliferating thymocytes and one for nonproliferating thymocytes. Although separate mechanisms, these two pathways do share some common features such as the activation of GR and the activation of caspases. The mechanism of glucocorticoid-mediated cell cycle arrest and apoptosis is not fully understood, but some cell cycle genes, e.g., c-myc, cyclin D3, and Cdk4, are regulated by glucocorticoids (140, 141) . Glucocorticoids upregulate the expression of the cyclin-dependent kinase inhibitor, p57 Kip2 , which is important in this glucocorticoids-mediated cell cycle arrest (142) .
In T cells, glucocorticoid-induced apoptosis is dependent on protein synthesis, but there is also evidence that it is dependent on repression of genes, such as c-myc. Comparison of the glucocorticoid-sensitive T-cell line 6TG1.1 and the glucocorticoid-resistant variant ICR27TK.3, which contains GR that is incapable of gene activation, indicates that repression of AP-1-induced gene activity is not involved in glucocorticoid-induced apoptosis in these cells. DNA fragmentation in the sensitive 6TG1.1 cells was inhibited by cyclohexamide, indicating that protein synthesis is required for glucocorticoid-induced apoptosis. Because inhibitory IκB molecule is induced by dexamethasone in these cells and because c-myc is regulated by NFκB, it has been suggested that glucocorticoid-induced apoptosis could occur by repression of gene transcription of the c-myc gene via glucocorticoid-induced transcription of IκB or another similar inhibitory factor (64).
Glucocorticoid-mediated apoptosis has also been described in monocytes. This occurs via the death receptor, CD95, a cascade for apoptosis that does not occur in T cells or thymocytes in response to glucocorticoids. In monocytes, glucocorticoids increase the expression of membrane CD95 and the ligand, CD95L, and also enhance their release. This activates a cascade involving caspase 8 and caspase 3 to induce apoptosis (143) .
EFFECTS OF GLUCOCORTICOIDS ON THYMOCYTE DIFFERENTIATION AND SELECTION
During the process of thymocyte differentiation, immature CD4 − CD8 − thymocytes rearrange the β gene locus of the T cell receptor (TCR) to express pre-TCR. These then divide and begin to express CD4 + and CD8 + and rearrange the α gene of TCR to express mature α/β TCR but at low levels. These CD4 + CD8 + low TCR cells then undergo selection, either positive or negative selection. Precisely what factors determine positive versus negative selection is not understood. In vitro in the presence of glucocorticoids alone, thymocytes/hybridomas undergo glucocorticoid-mediated apoptosis, whereas in the absence of glucocorticoids and the presence of activated TCR, these cells undergo activated-mediated apoptosis. Culture in the presence of both results in survival, and this balance between glucocorticoids and TCR has been termed mutual antagonism. To explain how selection occurs, it has been proposed that where the CD4 + CD8 + low TCR thymocytes do not recognize self-antigen/major histocompatability complex (MHC), there is a greater ratio of GR to TCR stimulation, and these cells will die of neglect through glucocorticoid-mediated apoptosis. If these thymocytes strongly recognize self-MHC, with a resultant higher ratio of TCR to GR activation, then these cells will die by negative selection through activated-mediated apoptosis. If there is an intermediate recognition of the MHC, a balance exists between the GR and TCR activation, and these cells will be selected by positive selection and will further differentiate into mature CD4 + or CD8 + thymocytes (144, 145) . Evidence for this mutual antagonism has been provided by studies in which inhibiting glucocorticoids results in thymocytes with a low-to-moderate avidity for self-MHC being forced into activated-mediated apoptosis (negative selection), rather than being rescued and undergoing positive selection as would occur in the presence of glucocorticoids (146) . Furthermore, in these conditions thymocytes that do not recognize self-MHC are rescued rather than undergoing glucocorticoid-mediated apoptosis (147) .
Thymocyte selection is active during fetal and neonatal period, but the levels of glucocorticoids circulating in the fetus are low because some level of protection from maternal glucocorticoids is provided by the placenta that contains high levels of the GC-catabolizing enzyme 11β-hydroxysteroid dehydrogenase. This apparent lack of glucocorticoids in the fetus and the necessity of them for thymocyte differentiation has led to the hypothesis that there may be local production of glucocorticoids in the thymus during development (145) . Indeed, cultured thymic epithelium cells do produce pregnenolone and deoxycorticosterone, and this production can be increased by ACTH. This production of glucocorticoids was specific to thymic epithelium cells and was not observed in cultures of thymocytes, macrophages, or dendritic cells. The P450 hydroxylase enzymes involved in the production of glucocorticoids, specifically corticosterone from cholesterol, have been shown in thymic epithelium cells (144, 145, 148) . Murine thymus also contains all the enzymes required for the production of glucocorticoids from cholesterol (149) .
In hybridomas, activated-mediated apoptosis is caused by the upregulation of the ligand for Fas, Fas ligand (FasL). Glucocorticoids prevent this upregulation of FasL, probably by the glucocorticoid-induced leucine zipper (GILZ) gene, but do not interfere with Fas itself. Another mechanism by which glucocorticoids may inhibit activated-mediated apoptosis is the activation of glucocorticoidinduced TNFR family related (GITR), which can inhibit CD3-mediated but not Fas-mediated apoptosis. In some diseases there could be a shift in this balance. Thus, in cases where glucocorticoids are overexpressed, this balance could be shifted such that a higher level of activated TCR cells survive and thus a greater population of thymocytes that recognize self could survive (145) . Indeed, in autoimmune disease models in animals and in patients with the autoimmune disease multiple sclerosis, there is a higher basal level of glucocorticoids (145, 150) .
The involvement of glucocorticoids in thymocyte differentiation and selection is still a matter of some controversy. Generation of transgenic antisense mice for the 3 untranslated region of GR under the control of a T cell-specific promoter led to mice with a twofold reduction of GR mRNA and protein. The thymus of transgenic homozygotes were 90% smaller than controls, and there was a decrease in CD4 + CD8 + thymocytes and a secondary decrease in CD4 + CD8 − and CD4 − CD8 + thymocytes, which indicates the necessity of glucocorticoids in thymocyte development and differentiation (144, 145) . However, in similar transgenics under the control of a different promoter (a neurofilament promoter), GR levels were decreased in all tissues, and there was an associated increase in circulating ACTH and corticosterone. Unlike the T cell-specific antisense animals, no difference in CD4 + CD8 + thymocytes was found (151) . In the GR knockin mice, which are deficient in dimerization and are therefore unable to activate gene transcription by GR, the thymocyte population was described as being normal although glucocorticoid-mediated apoptosis was reduced and no extensive analysis was performed (152) .
Recently, GR knockout mice have been described that die at birth [day 19 of embryogenesis (E19)]. However, during embryogenesis, i.e., up to E18, these animals have apparently normal thymocyte populations and T cell development, suggesting that GR in this case in not necessary for the entire process of T cell development and differentiation (153, 154) . The reason for these differences between animal models is not completely clear, but one significant difference between these different transgenic animals and knockin animals may result from secondary effects of the disrupted HPA axis (145) .
DISRUPTION OF THE HPA AXIS AND DISEASE

Animal Models
Animal models have been useful in understanding the pathogenesis of autoimmune/inflammatory disease. Many animal models exist in which a blunted HPA axis response has been associated with susceptibility to autoimmune/inflammatory diseases. These include the obese strain (OS) chicken as a model for autoimmune thyroiditis (155) , certain mouse lupus (SLE) models (156, 157) , and the inbred rat strains, LEW/N and F344/N rats, as described earlier. For a review on these and other animal models for inflammatory diseases, refer to Jafarian-Tehrani & Sternberg (158) . It should be noted, however, that many genes and many chromosome regions, each with small effect, contribute to susceptibility to autoimmune diseases, such as SLE (158a) and inflammatory arthritis (158b). While some of these linkage regions contain genes that regulate the HPA axis (158c), many are unrelated or unknown. Such genetic linkage and segregation studies also indicate that environmental factors play a large role in variance of disease expression. Thus, many different genetic and environmental factors contribute to autoimmune susceptibility in addition to HPA or neuroendocrine factors.
Human Diseases
HPA axis responsiveness differs greatly among individuals. Even in healthy individuals considerable intra-individual variability appears in HPA axis responses. Normal healthy volunteers have been subgrouped into high or low responders depending on the response of their HPA axis to stimuli (159, 160) . Disruptions in the HPA axis or glucocorticoid response could occur at many levels, including at the levels of the hypothalamus, pituitary, or adrenals, with changes in the expression of CRH, ACTH or cortisol, or changes in the sensitivity of the system to stimuli or suppressive factors. Once cortisol reaches its target tissue, there are then many steps to inducing gene activation, including entry into the cell, binding to GR, dimerization, translocation to the nucleus, and interaction with cofactors and the basal transcription machinery. It is conceivable that interruption of any of these pathways could result in a defective HPA axis or glucocorticoid response leading either to a lack of glucocorticoid production or to glucocorticoid resistance and resultant enhanced autoimmune/inflammatory disease. Depending on the specific defect, patients might or might not respond to exogenous glucocorticoid therapy. For further reading on glucocorticoid resistance syndromes, see the recent review by Kino & Chrousos (161) .
Disruptions in the HPA Axis or Glucocorticoid Response Leading to Glucocorticoid Sensitivity and Resistance
HPA AXIS In patient populations it is often difficult to dissect where a problem lies within the HPA axis, as many of its regulatory components cannot be directly measured in blood. Furthermore, inflammatory illness itself stimulates the HPA axis and alters its regulation (162, 163) . Since CRH cannot be measured directly in peripheral venous blood, CRH responsiveness must be deduced by measuring levels of ACTH and cortisol, which can be directly measured in peripheral blood. A blunted HPA axis resulting in low levels of glucocorticoids or a low glucocorticoid response to HPA axis stimulation has been implicated in a number of inflammatory diseases, including rheumatoid arthritis (164) (165) (166) (167) , systemic lupus erythematosus (SLE) (168), Sjogren's syndrome (169), allergic asthma and atopic skin disease (170) , and chronic fatigue syndrome (171, 172) . Patients with fibromyalgia have a low 24-h urinary free cortisol and a reduced response in the secretion of cortisol to HPA axis challenge (173) . In patients with multiple sclerosis and a high plasma basal cortisol level, a normal HPA axis response to oCRH but a reduced HPA axis response to AVP were observed (150) .
ADRENAL GLANDS Isolated glucocorticoid deficiency (IGD) is an autosomal recessive disorder, characterized by adrenocortical but not mineralocorticoid deficiency. Patients generally have low, undetectable cortisol levels that do not increase with treatment with exogenous ACTH. Also, the endogenous ACTH levels are high. Seventeen-point mutation and frameshifts in the receptor for ACTH have been identified that lead to this condition (174) (175) (176) . Thus, this disease results because defective ACTH receptors render the adrenal gland incapable of sensing the high ACTH levels that continue to be secreted by the pituitary. Thus, despite high levels of ACTH, little or no cortisol is produced. Novel mutations in the ACTH receptor have also been described in a patient with ACTH hypersensitivity syndrome. In this case the patient had normal cortisol levels but low, undetectable ACTH levels (177) . There have been some reports of patients with IGD developing autoimmune disease, such as organ-specific autoimmunity and autoimmune-mediated hypothroidism (178, 179) .
CORTISOL BINDING GLOBULIN (CBG)
The level of CBG in the blood limits the amount of free cortisol available. Changes in the expression of this protein or in its binding capacity could thus also affect the availability of cortisol. In New World primates, the lower levels of CBG and the lower affinity of cortisol for CBG have been associated with the higher circulating levels of glucocorticoids, which have been suggested to compensate for target organ resistance present in these mammals (180) . In some patients with long-standing Crohn's disease, a partial or complete resistance to steroids has been described; this resistance could be due to the increased expression of CBG in these patients, thereby limiting the bioavailability of glucocorticoids (181).
11β-HYDROXYSTEROID DEHYDROGENASE This enzyme catalyzes the conversion between an active glucocorticoid and inactive glucocorticoid (45) as described earlier. Thus, changes in this enzyme could result in differences in circulating or tissue glucocorticoid concentrations. In obese men, an impairment in the conversion of the inactive cortisone to the active cortisol was noted, indicating an impairment in the type I 11β-hydroxysteroid dehydrogenase and resulting in a drop in plasma cortisol levels (182) . A decrease in 11β-hydroxysteroid dehydrogenase mRNA in ulcerative colitis has also been demonstrated (183) .
GLUCOCORTICOID RECEPTOR Glucocorticoid resistance has been associated with mutation of GR. This has been particularly studied in relation to familial glucocorticoid resistance, a hereditary condition caused by a mutation in the GR with associated decreased number of receptors, decreased affinity or stability of the receptor, and a decrease in translocation of the receptor to the nucleus. To date the molecular defects of four families and one sporadic case have been determined. These include three different point mutations in the ligand-binding domain, one in the hinge region, and a deletion in the ligand-binding domain. [For a review see Kino & Chrousos (161) ].
A mutation in the GR may not be the only mechanism by which a change in this gene could affect the sensitivity to glucocorticoids. A polymorphism in codon 363 of GR has been described and associated with an increased sensitivity to glucocorticoids (184) . On the other hand, five polymorphisms in GR (including the one in codon 363) have been described in a normal population, and they cannot be correlated with glucocorticoid resistance (185) . Furthermore, there are patients with glucocorticoid resistance with no mutation detectable in GR, indicating that other defects in the steps in the pathway leading to gene activation by glucocorticoids could result in glucocorticoid resistance (186) . The GR has several phosphorylation sites of which the function is unclear. Mutation of these phosphorylation sites results in reduced transactivation capability of GR of a minimal promoter and reduces the stability of the GR protein (187) . Such changes as in the phosphorylation status of GR could have profound effects on GR function and be one method by which glucocorticoid resistance could occur.
GRβ has been proposed to act as a negative regulator of GR function. Thus, variations in the level of GRα and GRβ could also be associated with apparent glucocorticoid resistance, both initial and acquired. Glucocorticoid-resistant asthma has been associated with a higher expression of GRβ on the peripheral blood lymphocytes (188, 189) . GRβ expression is induced by cytokine treatment (190) ; thus as inflammatory disease progresses and cytokines are produced, induced GRβ expression could lead to exacerbation or development of glucocorticoid-resistant disease states (189) . Increased expression of GRβ has been shown in mononuclear blood cells from patients with glucocorticoid-resistant ulcerative colitis compared to similar cells from patients with glucocorticoid-sensitive disease (191) . A patient with generalized glucocorticoid resistance and chronic lymphoid leukemia has been described as having a decreased GR number and a reduced affinity for dexamethasone. This has been shown to be due not to a mutation in the GR but to a redistribution of GRα to GRβ with a reduced expression of GRα and an increased expression of GRβ (192) . Finally, a polymorphism in exon 9β of the human GRβ gene has been found to be associated with rheumatoid arthritis. This polymorphism increases the stability of GRβ and thus alters glucocorticoid sensitivity (193) . Taken together, these studies suggest that a variety of pre-and posttranslational changes in both forms of the GR are associated with autoimmune/inflammatory diseases.
COFACTORS Although to date a mutation in a cofactor has not been found associated with glucocorticoid resistance, a recent study into the glucocorticoid hypersensitive state associated with HIV-1 infection is worthy of comment. This hypersensitive state is specific to the immune system, the brain, musculoskeletal system, and fat and liver with maintenance of an intact HPA system. A HIV-1 accessory protein, virion-associated protein (Vpr), is able to act as a transcriptional activator to aid the replication of the HIV-1 virus. This protein contains a nuclear receptor binding motif (LXXLL) that binds directly to GR and cooperatively enhances transcription via SRC1a and p300/CBP cofactors (161, 194) . Recently, two sisters have been described with resistance to multiple steroids, and this may be due to a cofactor defect (195) .
TRANSPORT PROTEINS A group of ABC transmembrane transporters, MDR proteins, have been suggested to be involved in the active transport of glucocorticoids out of cells. Evidence exists that these proteins can transport glucocorticoids (196, 197 ; J. I. Webster, J. Carlstedt-Duke, unpublished data). These proteins are normally expressed in the blood-brain barrier, and knockout mice have been generated for the mouse mdr1a. In these knockout mice, an increase in the amount of dexamethasone present in the brain indicates that this protein is involved in the regulation of brain glucocorticoids (198, 199) . These proteins have been identified through their involvement in the multidrug resistance phenotype (200) . Recently, it was shown that patients with inflammatory bowel disease whom medical therapy had failed had an increase in the expression of the human MDR1 (ABCB1) (201) . This raises the possibility that these proteins may be another component that could affect the effectiveness of glucocorticoid therapy by reducing the concentration of the hormone within the cells and thus reducing the ligand availability for the GR. The novel orphan receptor PXR is involved in the upregulation of MDR1 (202) . Because PXR itself is activated by glucocorticoids among many other ligands (203) , this could possibly represent another mechanism by which acquired glucocorticoid resistance may develop.
OTHER NEUROENDOCRINE FACTORS AFFECTING IMMUNE FUNCTION
While this review has been focused on the HPA axis and glucocorticoid regulation of immunity and autoimmune/inflammatory disease, many other neural and neuroendocrine pathways connect with and regulate the immune system at multiple levels. These include the sympathetic nervous system and adrenergic factors and the peripheral nervous system and neuropeptides released by peripheral nerves.
Adrenergic Factors
The adrenergic sympathetic nervous system modulates local immune responses [for a comprehensive review of this topic, see Madden et al. (204) ]. Noradrenergic sympathetic nerve fibers run from the CNS to primary and secondary lymphoid organs, such as the thymus, spleen, and lymph nodes. These nerve terminals make synaptic-like connections with neighboring immune cells releasing noradrenalin (205) . The primary neurotransmitter released from sympathetic nerves, noradrenalin, exerts its effect at the target tissues through its receptor, the adrenergic receptor. Numerous cells of the immune system including lymphocytes and macrophages express adrenoreceptors. These are G-protein coupled receptors that can be divided into two subgroups-the α-and β-adrenergic receptors. These can be further subdivided into α 1 -, α 2 -, β 1 -, β 2 -, and β 3 -adrenergic receptors. The most important receptor in terms of the immune system is the β 2 -adrenergic receptor. Expression of α-and β-adrenergic receptors on T and B lymphocytes, neutrophils, mononuclear cells, and NK cells has been described. Activation of β 2 -adrenergic receptors results in an increase in cyclic AMP concentrations, which can modulate cytokine expression, i.e., decreasing TNF-α and increasing IL-8 (94) . It was originally thought that noradrenalin activated the β 2 -adrenergic receptor resulting in suppressed lymphocyte function. However, more recent data suggest that it modulates B cell function to protect against or aid progression of immune disease. If α-adrenergic receptors are present on immune cells, then activation of these receptors will lead to the activation of a different signaling cascade and the activation of MAP kinases. Activation of this cascade has different effects on cellular activity of immune cells than does activation via the β2 adrenergic receptor (206) (207) (208) . Furthermore, there appear to be regional difference in the effects of noradrenalin on immune function. Noradrenalin in the thymus is thought to play a role in modulation of thymocyte proliferation and differentiation, whereas in the spleen and lymph nodes it is thought to be involved in enhancement of the primary antibody response (205) .
Sex Hormones
The role of sex hormones, particularly estrogen, in the modulation of the immune system is an extensive and important area of research that is not reviewed here [for further reading, see Jansson & Holmdahl (209) ]. It is noteworthy that there is a greatly increased risk-in the range of two-to tenfold higher female-tomale ratio-of developing many autoimmune/inflammatory diseases such as SLE, rheumatoid arthritis, and multiple sclerosis in women compared to men. Regulation of the immune system by estrogens is of particular importance during pregnancy. In this case a balance between glucocorticoid and estrogen regulation probably plays a role in suppression of the maternal immune system to prevent rejection of the fetus (209) . Animal models have provided evidence for the importance of in vivo modulation of the immune system by the estrogen receptor (210, 211) . There are two receptors for estrogens. Estrogen receptor α (ERα) was the first to be described (212) . A second independent gene was identified in 1996 and termed ERβ (213) . Knockout mice have shown that both estrogen receptors are important in a gender-specific manner for thymus development and atrophy (214) . In addition, tamoxifen, an estrogen receptor antagonist, has some inhibitory effects on inflammation in LEW/N female rats (215) . Sex hormone regulation of the immune system also varies with aging; for example, expression of IL-6 is under the control of sex hormones such as estrogen and testosterone. In postmenopausal women and postandropausal men, the loss of regulation of IL-6 results in increased concentrations of IL-6 that is associated with the increased occurrence of inflammatory diseases with old age such as rheumatoid arthritis, bowel disease, and osteoporosis (84) .
CONCLUSION
In summary there are multiple neuro-anatomical, hormonal, and molecular mechanisms by which the CNS regulates immune function and plays a role in susceptibility to and pathogenesis of autoimmune/inflammatory disease. We have focused here on the HPA axis and glucocorticoids, the final effector end point of the HPA axis in regulating immunity. It is clear that even in the case of a single hormone, there are many potential mechanisms at gene, protein, receptor, signaling, and cell function levels where dysregulation could lead to disease. Given the many different hormonal and nerve pathways that regulate immunity, each with its own specific molecular end points, the potential mechanisms for pathogenesis of autoimmune disease(s) resulting from disruptions in these interactions is large. Nonetheless, a thorough understanding at all levels of the means by which the CNS and immune systems communicate will provide many new insights into the bidirectional regulation of these systems and the disruptions in these communications that lead to disease. Ultimately this understanding will inform new avenues of therapy.
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